Switch theme
Sign up to access all valuation multiples
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
2000
13
Last FY Revenue n/a
Last FY EBITDA -$12.7M
$31.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, MediciNova achieved revenue of n/a and an EBITDA of -$12.7M.
MediciNova expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MediciNova valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$12.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$19.7M | XXX | -$12.7M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$18.8M | XXX | -$11.0M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, MediciNova's stock price is $1.
MediciNova has current market cap of $68.2M, and EV of $31.8M.
See MediciNova trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $31.8M | $68.2M | XXX | XXX | XXX | XXX | $-0.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, MediciNova has market cap of $68.2M and EV of $31.8M.
MediciNova's trades at 31.8x EV/Revenue multiple, and -2.5x EV/EBITDA.
Equity research analysts estimate MediciNova's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MediciNova has a P/E ratio of -3.6x.
See valuation multiples for MediciNova and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $68.2M | XXX | $68.2M | XXX | XXX | XXX |
| EV (current) | $31.8M | XXX | $31.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 31.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.5x | XXX | XXX | XXX |
| EV/EBIT | -1.6x | XXX | -2.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.6x | XXX | -6.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMediciNova's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.0M for the same period.
MediciNova's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MediciNova's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MediciNova and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MediciNova acquired XXX companies to date.
Last acquisition by MediciNova was XXXXXXXX, XXXXX XXXXX XXXXXX . MediciNova acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was MediciNova founded? | MediciNova was founded in 2000. |
| Where is MediciNova headquartered? | MediciNova is headquartered in United States of America. |
| How many employees does MediciNova have? | As of today, MediciNova has 13 employees. |
| Who is the CEO of MediciNova? | MediciNova's CEO is Dr. Yuichi Iwaki,M.D.,PhD. |
| Is MediciNova publicy listed? | Yes, MediciNova is a public company listed on NAS. |
| What is the stock symbol of MediciNova? | MediciNova trades under MNOV ticker. |
| When did MediciNova go public? | MediciNova went public in 2006. |
| Who are competitors of MediciNova? | Similar companies to MediciNova include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of MediciNova? | MediciNova's current market cap is $68.2M |
| Is MediciNova profitable? | Yes, MediciNova is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
